Show Description +
Speaking on behalf of the African Descent and Glaucoma Evaluation Study (ADAGES), Aakriti Garg, MD, explains why patients with baseline 24-2 central visual field defects require more careful surveillance and potentially more aggressive treatment.
Posted: 3/01/2017
Speaking on behalf of the African Descent and Glaucoma Evaluation Study (ADAGES), Aakriti Garg, MD, explains why patients with baseline 24-2 central visual field defects require more careful surveillance and potentially more aggressive treatment.
Posted: 3/01/2017
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AGS: 2017.
Please log in to leave a comment.